daprodustat (Jesduvroq)
Jump to navigation
Jump to search
Indications
- treatment of anemia in renal dialysis patients (FDA-approved)*
- oral alternative to conventional erythropoiesis-stimulating agents
* not approved for patients not on renal dialysis
* patients must be on renal dialysis for at least 4 months[2]
Dosage
- start 4-12 mg PO QD depending upon prior does of erythropoiesis-stimulating agent
- adjust to blood hemoglobin 10-11 g/dL
- maximum 24 mg QD
Mechanism of action
- hypoxia-inducible factor prolyl hydroxylase inhibitor
More general terms
References
- ↑ Singh AK et al. Daprodustat for the treatment of anemia in patients undergoing dialysis. N Engl J Med 2021 Dec 16; 385:2325 PMID: https://www.ncbi.nlm.nih.gov/pubmed/34739194 https://www.nejm.org/doi/10.1056/NEJMoa2113379
Singh AK et al. Efficacy and safety of daprodustat for treatment of anemia of chronic kidney disease in incident dialysis patients: A randomized clinical trial. JAMA Intern Med 2022 Apr 4; [e-pub]. PMID: https://www.ncbi.nlm.nih.gov/pubmed/35377393 PMCID: PMC8981070 Free PMC article https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2790862 - ↑ 2.0 2.1 Monaco K FDA Panel Gives Thumbs Up to Anemia Pill for CKD Patients on Dialysis. But thumbs quickly turn down for the non-dialysis subset. MedPage Today October 27, 2022 https://www.medpagetoday.com/nephrology/anemia/101450
Zoler ML FDA Approves Daprodustat, First Oral Anemia Treatment. Medscape. Feb 2, 2023 https://www.medscape.com/viewarticle/987789